



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Daniel E.H. Afar et al. Examiner: Not yet assigned
Serial No.: 09/389,000 Group Art Unit: 1643
Filed: August 31, 1999 Docket: G&C 129.27-US-U2
Title: PHELIX: A TESTIS-SPECIFIC PROTEIN EXPRESSED IN CANCER

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on August 11, 2000.

By: 

Name: Karen S. Canady

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing a Certificate of Mailing under 37 CFR 1.8.
- ☒ Information Disclosure Statement and Form PTO-1449.
- ☒ Cited Reference(s).
- ☒ Return postcard.

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

Please charge any additional fees or credit any overpayment to Deposit Account No. 50-0494 of Gates & Cooper. A duplicate of this paper is enclosed.

Customer Number 22462.

GATES & COOPER
Howard Hughes Center
6701 Center Drive West, Suite 1050
Los Angeles, CA 90045
(310) 641-8797

By: 

Name: Karen S. Canady

Reg. No.: 39,927

KSC/sjm

(PTO TRANSMITTAL - GENERAL)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Daniel E.H. Afar et al. Examiner: Not yet assigned
Serial No.: 09/389,000 Group Art Unit: 1643
Filed: August 31, 1999 Docket: G&C 129.27-US-U2
Title: PHELIX: A TESTIS-SPECIFIC PROTEIN EXPRESSED IN CANCER

P#7



CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on August 11, 2000.

By: 
Name: Karen S. Canady

INFORMATION DISCLOSURE STATEMENT(37 C.F.R. §1.97(b))

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art". Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please direct any response or inquiry to the below-signed attorney at (310) 641-8797.

Respectfully submitted,


Daniel E.H. Afar et al.

By their attorneys,

GATES & COOPER
6701 Center Drive West, Suite 1050
Los Angeles, California 90045
(310) 641-8797

Date: August 11, 2000

KSC/sjm

By: 
Karen S. Canady
Reg. No.: 39,927